Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
4.290
+0.050 (1.18%)
At close: Feb 6, 2026, 4:00 PM EST
4.280
-0.010 (-0.23%)
After-hours: Feb 6, 2026, 7:13 PM EST
Precigen Revenue
Precigen had revenue of $2.92M in the quarter ending September 30, 2025, with 206.61% growth. This brings the company's revenue in the last twelve months to $6.31M, up 59.20% year-over-year. In the year 2024, Precigen had annual revenue of $3.93M, down -36.95%.
Revenue (ttm)
$6.31M
Revenue Growth
+59.20%
P/S Ratio
202.43
Revenue / Employee
$44,119
Employees
143
Market Cap
1.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.93M | -2.30M | -36.95% |
| Dec 31, 2023 | 6.23M | -20.68M | -76.87% |
| Dec 31, 2022 | 26.91M | 12.64M | 88.61% |
| Dec 31, 2021 | 14.27M | -88.91M | -86.17% |
| Dec 31, 2020 | 103.18M | 12.46M | 13.73% |
| Dec 31, 2019 | 90.72M | -60.46M | -39.99% |
| Dec 31, 2018 | 151.18M | -68.29M | -31.11% |
| Dec 31, 2017 | 219.46M | 28.54M | 14.95% |
| Dec 31, 2016 | 190.93M | 17.32M | 9.98% |
| Dec 31, 2015 | 173.61M | 101.68M | 141.35% |
| Dec 31, 2014 | 71.93M | 71.13M | 8,891.25% |
| Dec 31, 2013 | 800.00K | -12.97M | -94.19% |
| Dec 31, 2012 | 13.77M | 5.76M | 71.90% |
| Dec 31, 2011 | 8.01M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Innoviva | 388.52M |
| Immunocore Holdings | 379.59M |
| Tango Therapeutics | 66.50M |
| Agios Pharmaceuticals | 44.79M |
| uniQure | 15.75M |
| Upstream Bio | 2.80M |
| Celldex Therapeutics | 2.60M |
PGEN News
- 17 days ago - New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis - PRNewsWire
- 22 days ago - Precigen, Inc. (PGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 25 days ago - Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 4 weeks ago - Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Precigen Is Still A Buy After The Papzimeos Rally - Seeking Alpha
- 3 months ago - Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Precigen Reports Third Quarter 2025 Financial Results and Business Updates - PRNewsWire
- 3 months ago - Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 - PRNewsWire